Evidence map›Paper›PMID 42668306›Full record

ArticleNPJ genomic medicine2026

aiDIVA - hybrid AI for rare disease diagnostics using evidence-based, machine learning and language models.

Dominic Boceck, Lucia Laugwitz, Marc Sturm, Daniela Bezdan, Axel Gschwind, Tobias B Haack, Stephan Ossowski

Abstract read
In one paragraph

Article in NPJ genomic medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Dominic BoceckInstitute of Medical Genetics and Applied Genomics, University of Tübingen, Tübingen, Germany.
Lucia LaugwitzInstitute of Medical Genetics and Applied Genomics, University of Tübingen, Tübingen, Germany.
Marc SturmInstitute of Medical Genetics and Applied Genomics, University of Tübingen, Tübingen, Germany.
Daniela BezdanInstitute of Medical Genetics and Applied Genomics, University of Tübingen, Tübingen, Germany.
Axel GschwindInstitute of Medical Genetics and Applied Genomics, University of Tübingen, Tübingen, Germany.
Tobias B HaackInstitute of Medical Genetics and Applied Genomics, University of Tübingen, Tübingen, Germany.
Stephan OssowskiInstitute of Medical Genetics and Applied Genomics, University of Tübingen, Tübingen, Germany. stephan.ossowski@med.uni-tuebingen.de.

Funding

Deutsche Forschungsgemeinschaft EJP-RD Artemis: 542553983Deutsche Forschungsgemeinschaft, Germany 418081722Deutsche Forschungsgemeinschaft, Germany 514060894Else Kröner-Fresenius-Stiftung PRECISE.net 2.0European Commission Recon4IMD - GAP-101080997Eva Luise und Horst Köhler Stiftung 2026 Recognition AwardHorizon 2020, European Union 779257 (Solve-RD)Horizon Europe, European Union 101156595 (ERDERA)
6 · The paper itself

Abstract

Genome sequencing enables accurate detection of genetic variants and is transforming rare disease diagnostics. While data generation is scalable, prioritization and clinical interpretation remain challenging, often requiring expert manual classification. AI-driven decision support systems are therefore needed to assist in causal variant identification or to fully automate large-scale re-analysis of unsolved cases. Existing tools often estimate variant impact on protein function, but few integrate genomic, phenotypic, and clinical annotation data for diagnosis. We present aiDIVA, an ensemble-AI combining statistical and machine learning models trained on genomic and phenotypic data to identify causal variants among tens of thousands per patient. aiDIVA applies a random forest model to classify pathogenicity and generates evidence-based scores for dominant and recessive diseases. These predictions are integrated with clinical metadata to prioritize the most likely causal variants. Large language models further refine and explain results. The aiDIVA-meta model consolidates all scores into a ranked list. aiDIVA-meta reported the causal variant among the top-3 candidates in 97.4% of a pre-training collected cohort with prior evidence in ClinVar or HGMD, and in 93.3% of a post-training collected cohort of previously unreported variants.

Identifiers

PMID42668306
PMCPMC13526012

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.